UK markets closed

Sage Therapeutics, Inc. (SG7.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
11.35-0.07 (-0.61%)
At close: 04:05PM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 664.35M
Enterprise value 2.28M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.06
Price/book (mrq)1.04
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.91
52-week change 3-76.14%
S&P500 52-week change 326.27%
52-week high 355.00
52-week low 311.35
50-day moving average 315.75
200-day moving average 318.77

Share statistics

Avg vol (3-month) 349
Avg vol (10-day) 34
Shares outstanding 560.18M
Implied shares outstanding 660.41M
Float 847.8M
% held by insiders 112.47%
% held by institutions 194.60%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,489.18%

Management effectiveness

Return on assets (ttm)-31.98%
Return on equity (ttm)-54.72%

Income statement

Revenue (ttm)91.06M
Revenue per share (ttm)1.52
Quarterly revenue growth (yoy)139.90%
Gross profit (ttm)N/A
EBITDA -507.26M
Net income avi to common (ttm)-503.14M
Diluted EPS (ttm)-7.78
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)717.01M
Total cash per share (mrq)11.91
Total debt (mrq)3.31M
Total debt/equity (mrq)0.47%
Current ratio (mrq)12.22
Book value per share (mrq)11.73

Cash flow statement

Operating cash flow (ttm)-424.74M
Levered free cash flow (ttm)-232.9M